medRxiv preprint doi: https://doi.org/10.1101/2022.12.22.22283763; this version posted June 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

"Side effects of Vero cell vaccination against Covid-19 among medical students of Nepalgunj Medical College"-A Post Vaccination survey

Rupak KC[1], Sibika Malla[1], Aashish Pandey[1], Merina Shrestha[1], Saharoj Siddiqui[1], Suraj Adhikari[2], Niranjan KC[3], Rumi KC[4]

1. Nepalgunj Medical College, Banke, Nepal
2. Matrishishu Miteri Government Hospital, Gandaki, Nepal
3. Patan Academy of Health Sciences, Lalitpur, Nepal
4. Sahid Gangalal National Heart Center, Kathmandu, Nepal

Correspondence:

Dr. Rupak KC

Medical officer,

Department of Medicine, Nepalgunj Medical College.

Email: rupakdr1@gmail.com

ORCID ID: 0000-0002-8504-2378

Abstract

Background and aims: Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) is a highly transmissible virus causing Coronavirus disease (COVID-19). Its symptoms include fever, dry cough, and shortness of breath. Vaccine plays a significant role in controlling infectious disease and lesser health resources are used, and there is increased allocation of those resources for disease management. Vero Cell is an inactivated vaccine against COVID-19 manufactured by Sinopharm Company of China and recommended for people above 18 years by the World Health Organization. It is administered in two doses of 0.5 ml, 14-28 days apart. The goal of our study was to determine post-vaccination side effects of both the first(1st) and the second(2nd) dose among participants of Nepalgunj Medical College Teaching Hospital (NGMCTH), Kohalpur, Banke, Nepal.

Methods: A prospective cross-sectional study was conducted among undergraduate medical students and intern doctors of Nepalgunj Medical College. A comprehensive structured questionnaire was designed and distributed following each dose of vaccination. Data were collected from 6th January 2022 to 6th April 2022 and entered in Microsoft Excel and analyzed using the statistical package for social sciences (SPSS) version 22. Analyzed data were presented using simple descriptive statistics with appropriate tables.

Results: Out of 156 participants, the majority were males (66.7%), within the age group of 21-24. The most frequently encountered symptom was pain at the injection site, predominantly seen in males. Among all the tested variables, the second dose of vaccination showed a significant association with sex. All the predominant symptoms exhibited a significant association following vaccination, except for pain at the injection site (p-value <0.05).

Conclusions: Vaccine has proven to be a lifesaving breakthrough during the peak of the COVID-19 outbreak and has been precisely efficacious in a developing country like Nepal.

KEYWORDS:
Covid-19; Nepal; Post- Vaccination Side-effects; Vaccination; Vero Cell

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.22.22283763; this version posted June 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

INTRODUCTION

The virus that is the root cause of the highly threatening global pandemic has been designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the coronavirus disease (COVID-19). (1)As per the reports, this virus was first discovered in persons exposed to a seafood wholesale wet market in Wuhan, China. (2)By the 31st of December, the Wuhan Municipal Health Commission had given out its alert. (3)Soon this disease enveloped the entire world and was announced as a pandemic by the World Health Organization on the 11th of March, 2020. (4)Till February 3, 2022, a total of 385,967,643 cases of COVID-19 have been confirmed out of which 5,721,171 has died and 305,840,220 has been recovered. (5)

SARS-CoV-2 is the third coronavirus after SARS-CoV (2002) and MERS-CoV (2012) which has a high case fatality rate of 4.8%. (6,7)It is a single-stranded, spherical, or pleomorphic enveloped RNA virus whose club-shaped protrusions cover them like a crown and this is also the reason for its naming. (8,9) SARS-CoV-2 can be transmitted through direct contact, air, fomite, or fecal-oral route. Similarly, blood-borne, mother-to-child, or animal-to-human transmission of this virus has also been found. (10) Its key symptoms include fever, dry cough, and shortness of breath. Pneumonia is a major complication. (11)

The first positive case of COVID-19 in Nepal was confirmed in a girl who returned from Wuhan Institute of Technology, Wuhan, China on the 13th of January, 2020. (12) As of 12 February 2021, the total confirmed cases there were 972,632 out of which 11,882 had died. (5) The only hope in this dark phase is the vaccine that can end the pandemic. Safe and effective vaccines are a game-changing tool. Vaccine plays a significant role in controlling infectious disease, reduction of the use of health services because of infectious diseases, and leaving more resources for the prevention and treatment of other diseases. (13) It prevents people from being infected or getting gravely sick. It prevents the person from spreading COVID-19 to others, thus making it difficult for the disease to escalate, contributing to herd immunity. (14,15) Till 2 February 2022, 33 vaccines have been approved for clinical use and 65 vaccines are in their phase three trials. (16) The vaccination program has begun in Nepal on 27th January 2021 after India provided one million doses of the Covid-19 Covishield vaccine, developed by the University of Oxford and pharmaceutical giant AstraZeneca and locally produced by the Serum Institute of India, the world's largest vaccine company. (17) At the beginning of March, COVAX, an international vaccine-sharing scheme supported by the United Nations, supplied 348,000 doses of Covishield. Beijing delivered 800,000 doses of Vero Cell under grant assistance at the end of March. Again, in June, an additional 1 million doses of Vero Cell under a Chinese grant then arrived Nepal. (18)

The Vero cell is an inactivated vaccine manufactured by Sinopharm Company of China which is recommended safe to be used for people above 18 years by the World Health Organization. It is administered in two doses of 0.5 ml each. The second dose is administered 14-28 days after the first one. (19) According to the global health agency's estimation, the Vero cell's overall efficacy is about 78%. (20) Sinopharm (Vero Cell) vaccine has been evidently proven to be 50.4% effective in preventing Covid-19 and 94% effective in preventing deaths. (21)

Many people who have been vaccinated are experiencing side effects in one form or the other. Outside of clinical trials situation, only a few data are available which has assessed its safety. This research aims to assess the post-vaccination side effects of Vero Cell (Sinopharm) in undergraduate medical students and medical interns of Nepalgunj medical college.

METHODS

Study design and settings:

A prospective cross-sectional study was conducted among undergraduate medical students and intern doctors of Nepalgunj Medical College after receiving ethical approval from the institutional review

medRxiv preprint doi: https://doi.org/10.1101/2022.12.22.22283763; this version posted June 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

committee of the college. The confidentiality of all the participants was taken into account. Participants promptly received the 1st dose and when the second dose became accessible, our vaccination was completed upon receiving the 2nd dose. The study period spanned from 6th January 2022 to 6th April 2022, a period of 3 months.

Study Participants

156 participants were included in the study constituting M.B.B.S students from 3rd year to final year and Intern Drs of Nepalgunj medical college, Banke, Nepal.

Eligibility criteria

Participants who received two doses of the vaccination were eligible to participate in the study. Those participants who didn't provide their consent for the study and those who have previously been vaccinated with other vaccines like Covishield, Pfizer; etc., and students from basic science were excluded.

Questionnaire administration

A comprehensive structured questionnaire was designed and distributed among the participants following each dose of vaccination, capturing the demographic information and the post-vaccination symptoms. Subsequently, the results were collected and analyzed two weeks later. Recall bias and information bias may include.

Statistical Analysis:

Data were collected using a comprehensive structured questionnaire. The eligible participants were given the questionnaire twice, after administering each dose of vaccine. Data were collected two weeks apart following each dose of vaccination. Collected data were entered in Microsoft Excel 2019 MSO (Version 2021). The presence or absence of symptoms was indicated as 1 or 0. If any symptom was observed within the total duration of the study, we marked it as 1 for symptom seen, and 0 for not seen. Any specific post-vaccination effects seen over any duration were marked as observed. Data were then analyzed statistically using Statistical Package for Social Sciences (SPSS Version 2022). The normality of data was tested using the Shapiro-Wilk test. The Chi-Square test was used to observe the association between the categorical variables and symptoms of 1st and 2nd doses of the vaccination. The associations between the categorical variables and individual symptoms were also studied. Also, to comprehend the association between the frequency of vaccination (1st and 2nd dose) and symptoms presented within the duration of the study, the Wilcoxon Signed Rank test was implemented. The evaluated data were presented in the form of tables and the association is considered to be significant if the P-value is less than 0.05.

RESULTS

A total of 156 participants were included in the study, the majority of participants consisted of males (66.7%), primarily comprising intern doctors within the age group of 21-24 years. (**Table 1**)

About 80.1% of the participants exhibited one or more symptoms after the first dose, which decreased to 66% after the second dose of vaccination. Both doses of the vaccination demonstrated a greater effect in males with the effect being more pronounced following the 2nd dose. Females also exhibited a response, although not as significant as that observed in males. (**Table 2**)

The predominant symptoms were pain at the injection site, myalgia, fatigue, itching, and fever. Pain at the injection site was the most commonly reported side effect (48.1 %) accompanied by myalgia (29.5 %) following 1st dose of the vaccination. However, in 2nd dose, pain at the injection site (48.7%) was subsequently followed by fatigue (16%). The emergence of the sore throat and runny nose occurred only during the administration of the 2nd dose of the vaccination. Both doses of vaccination yielded unreported side effects which included diarrhea, difficulty in breathing, tingling sensation, or anaphylactic reaction. The vast majority of the symptoms appeared within 12 hours post-vaccination. (**Table 3**)

medRxiv preprint doi: https://doi.org/10.1101/2022.12.22.22283763; this version posted June 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1. Demographic parameters

S.N.	Parameter	No. (%)
1.	**Gender**	Male 104 (66.7%) Female 52 (33.3%)
2.	**Year of Study**	Third year 38 (24.4%) Final year 57 (36.5%) Intern doctors 61 (39.1%)
3.	**Age**	21-24 yrs. of age 98 (62.8%) 25-28 yrs. of age 58 (37.2%)

Table 2. Symptoms following the first and second dose of vaccination

Dose	Symptoms	Male (%)	Female (%)	Total (%)
1st Dose	Seen	87 (69.6)	38(30.4)	125 (80.1)
	Not Seen	17(57.8)	14 (45.2)	31 (19.9)
2nd Dose	Seen	76 (73.8)	27 (26.2)	103 (66)
	Not Seen	28 (52.8)	25(47.2)	53 (34)

,

The frequently encountered post-vaccination symptoms were more prevalent in males than in females, and the occurrence of post-vaccination pain at the injection site was more frequently observed in males following the 2nd dose. With the exception of pain at the injection site, all other major symptoms exhibited a declining trend subsequent to the vaccination. (**Supplementary file, Table 1**)

Table 3. Frequency and Duration of Symptoms

Symptoms	Dose 1	Maximum Duration of Appearance	Dose 2	Maximum Duration of Appearance
Pain at the Injection site	75	66(Within 12 hour)	76	72(Within 12 hour)
Myalgia	46	42(Within 12 hour)	21	17(Within 12 hour)
Fatigue	42	34(Within 12 hour)	25	23(Within 12 hour)
Itching	30	26(within 12 hour)	12	12(Within 12 hour)
Fever	27	19(Within 12 hour)	11	10(Within 12 hour)
Headache	10	9(Within 12 hour)	9	8(Within 12 hour)
Dizziness	9	8(Within 12 hour)	1	1(Within 12 hour)
Skin Rash	7	6(Within 12 hour)	3	3(Within 12 hour)

medRxiv preprint doi: https://doi.org/10.1101/2022.12.22.22283763; this version posted June 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Redness	4	4(Within 12 hour)	Not seen	Not seen
Joint Pain	3	3(Within 12 hour)	4	4(Within 12 hour)
Nausea and Vomiting	3	3(Within 12-24 hour)	Not seen	Not seen
Swelling	1	1(Within 12 hour)	1	1(Within 12 hour)
Cough	1	1(Within 24-48 hour)	3	3(Within 12 hour)
Sneezing	1	1(Within 24-48 hour)	1	1(Within 12-24 hour)
Sore Throat	Not seen	Not seen	4	4(Within 12 hour)
Runny Nose	Not seen	Not seen	1	1(Within 12-24 hour)
Diarrhea	Not seen	Not seen	Not seen	Not seen
Difficulty in breathing	Not seen	Not seen	Not seen	Not seen
Tingling Sensation	Not seen	Not seen	Not seen	Not seen
Swollen Lymph Node	Not seen	Not seen	Not seen	Not seen
Fainting	Not seen	Not seen	Not seen	Not seen
Anaphylaxis	Not seen	Not seen	Not seen	Not seen

The normality of data distribution was tested using the Shapiro-Wilk test. Our data were non-normal in distribution. Chi-square test was used to see the association between the overall symptoms observed post-vaccination with determinant variables (age, sex and years of study). Among all the tested variables, the post-vaccination side effects after 2nd dose showed a significant association with sex, in contrast to the 1st dose. (**Table 4**) We conducted an analysis of the major symptoms observed after both doses of vaccination. Our research revealed a significant link between sex and fever after the first dose. Furthermore, we found a significant difference in pain at the injection site and myalgia following the first dose among two age groups (<25 years and >25 years). **(Supplementary file, Table 2 and Table 3)**

Further, the association was delineated using Wilcoxon Signed Rank test. Major Symptoms that occurred were analyzed for the association with subsequent doses of vaccination. Interestingly there was no such association between pain at the injection site with the doses of vaccination (p-value >0.05) though it was the major symptom recorded in our study. Other symptoms like myalgia, fatigue, itching, sore throat, and fever were found to be significantly associated with the subsequent doses of vaccination with p-value less than 0.05. (**Table 5**)

Table 4. Variables associated with overall symptoms post-vaccination.

Variables	1st Dose	2nd Dose
Age	0.205	0.389
Sex	0.09	**<0.05**
Years of Study	0.52	0.09

Table 5. Association of major Symptoms with subsequent doses of vaccination.

Symptoms	P-value
Pain at the injection site	0.7

medRxiv preprint doi: https://doi.org/10.1101/2022.12.22.22283763; this version posted June 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Myalgia	**<0.05**
Fatigue	**<0.05**
Itching	**<0.05**
Fever	**<0.05**
Headache	0.8
Sore Throat	**<0.05**
Runny nose	0.3

Discussion:

Subsequent to the vaccination received, the majority of the symptoms were reported among the age group 21-24 years, with a comparable observation in the study conducted following Covishield vaccination in Nepal where the study reported maximum symptom presentation among individuals aged 18-30 years. (22) The greatest number of adverse effects was predominantly reported among the male participants post-vaccination with 69.6% in the first (1st) dose and 73.8% in the second (2nd) dose. Contrary to our study, the findings were more pronounced in the females in the study conducted in Sinopharm (Vero cell) at Patan, Nepal, and in the United Arab Emirates. (23,24) The same study was conducted examining the adverse effect of the ChAdOx1 nCoV-19 (Covishield) vaccine which again revealed a higher preponderance in females. (22,25)

In a study involving 156 participants, 80.1% and 66% of the total participants presented with at least one symptom subsequent to the first(1st) and second(2nd) dose of vaccination respectively whereas the observed effects are more pronounced in other vaccines including the Pfizer-BioNTech vaccine conducted in Jordan having 83.7% in the1st dose and 88.7% in the 2nd dose and ChAdOx1 nCoV-19 (Covishield) vaccine conducted in Nepal reported 91.6%, as opposed to ours. Similarly, Moderna and Pfizer also demonstrated a greater effect after the second dose than the first. (25–27) However, the effect of the Vero cell vaccination in a study conducted at Patan, demonstrates a lesser effect exhibiting 19% in 1st dose and 11.2% in 2nd dose. (24) A notable decrease in the observed effect is seen from 80.1% in the 1st dose to 66% in the 2nd dose in our study. A similar pattern of effect was seen with Vero cell and Covishield in the study conducted in Nepal. (22,24) In contrast to our study, a reciprocal relationship was observed between the dose and the symptoms in a study conducted in Sinopharm (Vero Cell) by Balsam et.al.(23) Similarly, adverse effect was also observed to be increased from the 1st dose to the 2nd dose with Pfizer-BioNTech, AstraZeneca, and Sinopharm (Vero cell) vaccines in the study conducted in Jordan. (26) The most pronounced symptoms were observed within 12 hours following vaccination which is in coherence with the study conducted by Poudel et.al.(22)

Among the 156 participants included in the study, Pain at the injection site emerged as the predominant symptom constituting about 60% of the reported presentation following 1st dose of the vaccination and 73.7% following the 2nd dose. The outcome of our study was consistent with the findings conducted among the HCWs of Jordan which illustrates that pain at the injection site was the most common presentation following both doses of vaccination. (26) A similarly significant finding with Vero cell was seen in a study conducted in Patan, Nepal, and in the United Arab Emirates where again pain at the injection site was found to be the most common presenting symptom. (23,24) Based on the result of the study by the World Health Organization, Pain at the injection site once again emerged as the prevailing symptom (≥1 in 10). (28)Muscle pain or myalgia ranked as the second most prevalent symptom with an average of 58.71% following both doses. Conversely, it contradicts from the study conducted by Balsam et.al where only 6.3% at the 1st dose and 5.9% at the 2nd dose of the total study population presented with myalgia. (23) On average, 58.71% % of the participants presented with fatigue which is regarded as the 3rd most common symptom presentation in our study which diverges from the study conducted by Osama Abu-Hammad et.al and Balsam et.al.(23,26) The manifestation of headache was more pronounced in our study, accounting for 8% in the 1st dose and

medRxiv preprint doi: https://doi.org/10.1101/2022.12.22.22283763; this version posted June 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

8.7% in the 2nd dose, whereas it is less prevalent in the study conducted at Patan, Nepal accounting for 2.9% in the 1st dose and 1.6% in the 2nd dose. (24) However, in the study on Vero cell conducted by Balsam et.al, the headache was found to be 9.6% in the 1st dose and 10% in the 2nd dose. (23) On average, 33.33% % of the total participants exhibited fever which exceeds the average number of presentations in the study conducted by Osama Abu-Hammad et.al and Balsam et.al**.** (23,26)

In a developing country like Nepal with finite resources, the Vero cell has proven to be the most suitable one because of its easy accessibility, availability, and good efficacy. (29) Correlating our study with other studies, Pain at the injection site, Myalgia and Fatigue were found to be the top three commonest presentations whilst Pain at the injection site was commonest among all the studies. The least common symptoms included swelling, sneezing, sore throat, nausea, vomiting, dizziness, cough, and runny nose. (24,30–32)

In a study conducted at Patan, Nepal, we discovered a significant association between sex and symptoms after both doses of vaccination, but not with age. This pattern was repeated following the Covishield vaccination, which again showed an association between sex and symptoms. Despite the differences between the vaccine used, the results were consistent. Our study indicated that the symptoms were more strongly associated with sex following the 2nd dose than the 1st, but not with age and years of study. In a study conducted at Jordan, Pfizer, Sinopharm, and AstraZeneca combinedly showed a significant association with age only after the 1st dose whereas there was no significant association with sex. (24–26)

Upon analyzing the individual symptoms, in our study we found that gender and fever were significantly associated after the 1st dose, but no at any other symptoms. Pain at the injection site and fever was found to be significantly associated with age following the 1st dose of the vaccination. But no significant differences were observed following the 2nd dose. In contrast to our findings, a study conducted by Balsam et.al showed that gender was significantly associated with fatigue after the 1st dose, while the 2nd dose was found to be associated with pain at the injection site and fatigue. Similarly, age showed a significant association with pain at the injection site, nausea, and myalgia following the 1st dose, whereas only fatigue was found to be significantly associated following the 2nd dose. Contradictory, to the overall findings, age and sex were not significantly associated with individual symptoms in a study conducted by Osama Abu-Hammad et.al.(23,26)

Conclusion:

During the peak of the COVID-19 outbreak, when its impact was most severe and survival was paramount, the emergence of vaccine proved to be a lifesaving breakthrough, offering a critical ray of hope. The vaccine has always been a boon to human existence and a pivotal turning point in the survival of mankind. The effectiveness of the vaccine requires no further validation.

Based on our comprehensive study, following both doses of vaccination, Pain at the injection was found to be the commonest presentation which carried no long-term side effects, and all the symptoms resolved within 72 hours of presentation.

This is precisely why Sinopharm (Vero Cell) is highly favored, as it demonstrates remarkable efficacy without compromising on affordability in a developing country like NEPAL. Nevertheless, a larger study on the general population including all age groups is highly recommended to detect all of the side effects.

AUTHOR CONTRIBUTIONS

Rupak KC: Conceptualization; ethical approval; data collection; software; writing-original draft preparation; supervision; writing-review & editing. **Sibika Malla:** Resources; methodology; data collection; writing-original draft preparation; writing-review & editing. **Aashish Pandey:** Methodology, software, writing-original draft preparation; writing-review & editing. **Merina Shrestha:** Investigation; resources; ethical approval; supervision. **Saharoj Siddiqui:** writing-original

medRxiv preprint doi: https://doi.org/10.1101/2022.12.22.22283763; this version posted June 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

draft preparation; writing-review & editing **Suraj Adhikari:** Project administration; resources; software; writing-original draft preparation; supervision; writing-review & editing. **Niranjan KC:** Project administration; data collection; resources; writing-review & editing. **Rumi KC:** Resources; data collection; project administration; writing-review & editing.

ACKNOWLEDGEMENT

We would like to acknowledge Dr. Prabesh Pant, Assistant Professor, Department of Neuro-medicine, COMS, Chitwan, Banke for his invaluable support and guidance. We would like to acknowledge Dr. Dhan Bahadur Shrestha for his cooperation and valuable insight into this paper. We would also like to express our sincerest gratitude towards our participants for their time and co-operation.

LIMITATIONS

Our study was conducted in a small center where the overall population was not included. All the spectra of side effects of the vaccine in a healthy group population were difficult to appreciate. Also, recall bias was significant.

CONFLICT OF INTEREST STATEMENT

No any supporting source or financial relationship has been involved throughout the study. The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT

The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.

ETHICS STATEMENT

Ethics approval for the research project was obtained from the NGMCTH Ethics Review Committee (Ref.463/078-079) on 29 December 2021.

TRANSPARENCY STATEMENT

The lead author Rupak KC affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

All co-authors have read and approved the final version of the manuscript. The lead author Rupak KC had full access to all of the data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis.

ORCID ID: 0000-0002-8504-2378

REFERENCES:

1. World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization [Internet]. 2023 [cited 2023 Jun 15]; Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it

2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine. 2020 Feb 20;382(8):727–33.

3. World Health Organization. Listings of WHO's response to COVID-19. World Health Organization [Internet]. 2020 Jun 29 [cited 2023 Jun 15]; Available from: https://www.who.int/news/item/29-06-2020-covidtimeline

medRxiv preprint doi: https://doi.org/10.1101/2022.12.22.22283763; this version posted June 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

4. 'Ducharme J. World Health Organization Declares COVID-19 a "Pandemic." Here's What That Means. TIME [Internet]. 2020 Mar 11 [cited 2023 Jun 15]; Available from: https://time.com/5791661/who-coronavirus-pandemic-declaration/

5. Worldometers. Coronavirus cases. Worldometers. 2021.

6. Zhu Z, Lian X, Su X, Wu W, Marraro GA, Zeng Y. From SARS and MERS to COVID-19: A brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. Vol. 21, Respiratory Research. BioMed Central Ltd; 2020.

7. World Health Organization. Coronavirus disease (COVID-19) Weekly Epidemiological Updates and Monthly Operational Updates. World Health Organization. 2020 Jan 26;

8. Tyrrell DAJ, Myint SH. Coronaviruses. Clinical Virology [Internet]. 1996 Mar 7 [cited 2023 Jun 15];1243–65. Available from: https://www.ncbi.nlm.nih.gov/books/NBK7782/

9. 'Paul A. Coronavirus [Internet]. John Hopkins Medicine. 2021 [cited 2023 Jun 16]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540143/all/Coronavirus

10. World Health Organization. Transmission of SARS-CoV-2: implications for infection prevention precautions. World Health Organization [Internet]. 2020 Mar 29 [cited 2023 Jun 16]; Available from: https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions

11. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19) [Internet]. National Centre for Immunization and Respiratory Disease (U.S.).Division of Viral Diseases. 2020 [cited 2023 Jun 16]. Available from: https://stacks.cdc.gov/view/cdc/89980

12. Bastola A, Sah R, Rodriguez-Morales AJ, Lal BK, Jha R, Ojha HC, et al. The first 2019 novel coronavirus case in Nepal. Vol. 20, The Lancet Infectious Diseases. Lancet Publishing Group; 2020. p. 279–80.

13. Why are vaccinations needed? - THL [Internet]. [cited 2023 Jun 16]. Available from: https://thl.fi/en/web/infectious-diseases-and-vaccinations/information-about-vaccinations/why-are-vaccinations-needed-

14. Vaccines for COVID-19 | CDC [Internet]. [cited 2023 Jun 16]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html

15. Get the facts about COVID-19 vaccines - Mayo Clinic [Internet]. [cited 2023 Jun 16]. Available from: https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/coronavirus-vaccine/art-20484859

16. Vaccines – COVID19 Vaccine Tracker [Internet]. [cited 2023 Jun 16]. Available from: https://covid19.trackvaccines.org/vaccines/

17. Nepal begins first phase of Covid-19 vaccination drive [Internet]. [cited 2023 Jun 16]. Available from: https://kathmandupost.com/health/2021/01/27/nepal-begins-first-phase-of-vaccination-drive-against-covid-19

medRxiv preprint doi: https://doi.org/10.1101/2022.12.22.22283763; this version posted June 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

18. All you need to know about Nepal's vaccination status [Internet]. [cited 2023 Jun 16]. Available from: https://kathmandupost.com/health/2021/12/06/all-you-need-to-know-about-nepal-s-vaccination-status-1638759390

19. Platform description of vaccine. 2001.

20. What to know about the Sinopharm COVID-19 vaccine's side effects [Internet]. [cited 2023 Jun 16]. Available from: https://www.medicalnewstoday.com/articles/sinopharm-covid-19-vaccine-should-you-worry-about-the-side-effects

21. 'Rochabrun M, 'Liu R. Peru study finds Sinopharm COVID vaccine 50.4% effective against infections. REUTERS [Internet]. 2021 Aug 13 [cited 2023 Jun 16]; Available from: https://www.reuters.com/world/americas/peru-study-finds-sinopharm-covid-vaccine-504-effective-against-infections-2021-08-13/

22. Poudel KM, Shah N, Prakash M, Deo SK, Bhandari S, Poudel TR. Determinants of associated events following AZD1222 (Covishield) vaccination in a high-risk population in Nepal. BMC Infect Dis. 2022 Dec 1;22(1).

23. Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. International Journal of Infectious Diseases. 2021 Oct 1;111:219–26.

24. Aryal S, Devbhandari RP, Shrestha A, Rajbhandari P, Shakya T, Tuladhar S, et al. Adverse events following Immunization with Sinopharm (Vero Cell) inactivated COVID-19 vaccine. General Section Original Article Journal of Patan Academy of Health Sciences [Internet]. 2021;8(2):18–24. Available from: https://doi.org/10.3126/jpahs.

25. Gautam A, Dangol N, Bhattarai U, Paudel S, Poudel B, Gautam S, et al. ChAdOx1 nCoV-19 vaccine and its self-reported adverse events: a cross-sectional study from Western Nepal. J Glob Health Rep. 2021 Jul 21;5.

26. Abu-Hammad O, Alduraidi H, Abu-Hammad S, Alnazzawi A, Babkair H, Abu-Hammad A, et al. Side effects reported by jordanian healthcare workers who received covid-19 vaccines. Vaccines (Basel). 2021 Jun 1;9(6).

27. 'Elterman K, 'Aungst C. Why Are Pfizer and Moderna Vaccines' Side Effects Worse After the Second Shot? GoodRx Health [Internet]. 2021 Oct 28 [cited 2023 Jun 18]; Available from: https://www.goodrx.com/conditions/covid-19/why-side-effects-worse-after-second-covid-19-shot

28. Tozzi AE, Asturias EJ, Balakrishnan MR, Halsey NA, Law B, Zuber PLF. Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use. Vaccine [Internet]. 2013 Oct 17 [cited 2023 Jun 16];31(44):5041–6. Available from: https://pubmed.ncbi.nlm.nih.gov/24021304/

29. WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations [Internet]. [cited 2023 Jun 16]. Available from: https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations

30. Background document on the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm, 7 May 2021 [Internet]. [cited 2023 Jun 16].

medRxiv preprint doi: https://doi.org/10.1101/2022.12.22.22283763; this version posted June 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BIBP-background-2021.1

31. Sinopharm [Vero Cell]- Inactivated, COVID-19 vaccine [Internet]. [cited 2023 Jun 16]. Available from: https://www.who.int/publications/m/item/sinopharm-vero-cell---inactivated-covid-19-vaccine

32. WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations [Internet]. [cited 2023 Jun 16]. Available from: https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations

medRxiv preprint doi: https://doi.org/10.1101/2022.12.22.22283763; this version posted June 25, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .